Form 4: Director Bridget Ross Trades Lematire Vascular Shares

Director Bridget A. Ross reported transactions involving Lematire Vascular Inc. common stock, including option exercises and share disposals.

Summary

• Director Bridget A. Ross of Lematire Vascular Inc. engaged in several transactions on May 7, 2026.
• Ross acquired 3,444 shares of common stock upon exercising stock options at a price of $48.60 per share.
• Additionally, Ross acquired 1,600 shares of common stock upon exercising stock options at a price of $47.19 per share.
• Following these acquisitions, Ross disposed of 5,044 shares of common stock at a weighted average price of $111.0956 per share, with individual trades ranging from $111.00 to $111.30.
• After these transactions, Ross beneficially owns 3,942 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale of shares by a director can sometimes be perceived negatively, the context of exercising options at a lower price and selling at a higher price is a common and often expected outcome of equity compensation. The volume of shares sold needs to be considered in relation to the director's total holdings and the company's overall trading volume to determine a more definitive sentiment.

Positives

• Director Ross exercised stock options, indicating potential for personal investment and belief in the company's value.
• The disposal of shares occurred at a significantly higher price ($111.0956) than the exercise price of the options ($48.60 and $47.19), suggesting a profitable transaction for the reporting person.

Negatives

• A significant number of shares (5,044) were sold by a director, which could be interpreted negatively by the market, especially if it represents a substantial portion of their holdings or if it occurs without a clear strategic reason.

Risks

• The disposal of a large number of shares by a director could signal a lack of confidence in future price appreciation, potentially impacting investor sentiment.
• While not explicitly stated as a risk, the significant difference between the option exercise price and the sale price could be subject to scrutiny regarding executive compensation and insider trading perceptions.

Future Outlook

No explicit forward-looking statements or guidance were provided in this Form 4 filing, which primarily reports past transactions.

Management Comments

• The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The exercise of options and subsequent sale of shares by a director is common, particularly when options are vested and the stock price has appreciated significantly. The key for investors is to understand the volume of shares traded relative to the insider's total holdings and the overall market float, as well as any patterns of buying or selling.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a director as a potential signal, though the profitable nature of the transaction (option exercise followed by sale) mitigates some negative sentiment.
• Employees: May view the director's profitable stock option exercise and sale as a positive indicator of the company's stock performance.
• Creditors: Unlikely to be directly impacted by this specific insider transaction.

Next Steps

• Monitor future Form 4 filings from Bridget A. Ross and other Lematire Vascular Inc. insiders for any patterns of buying or selling.
• Analyze the company's overall financial health and strategic announcements to contextualize insider trading activity.

Key Dates

Keywords

Form 4, Insider Trading, Stock Options, Share Disposal, Beneficial Ownership, Lematire Vascular, Director Transactions, SEC Filing